Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Doxycycline Tablets USP in strengths of 50 mg, 75 mg, 100 mg and 150 mg. The drug is a tetracycline antibiotic that fights bacteria in the body and is used to treat many different bacterial infections, such as acne, urinary tract infections, intestinal infections, eye infections, gonorrhea, chlamydia, periodontitis (gum disease) and others. It will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad
The group now has more than 155 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
